The groundbreaking success of Viagra undeniably transformed the medication landscape, but investing in companies primarily reliant on generic versions presents a challenging picture. Despite early returns were significant, the end of patents and the rise of discounted alternatives have eroded market share. Thus, a thorough analysis of ongoing incom